{"id":326674,"date":"2010-02-16T12:10:17","date_gmt":"2010-02-16T17:10:17","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=63563"},"modified":"2010-02-16T12:10:17","modified_gmt":"2010-02-16T17:10:17","slug":"icahn-boosts-genzyme-stake","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/326674","title":{"rendered":"Icahn Boosts Genzyme Stake"},"content":{"rendered":"\n
Life Sciences<\/a>, Biotech<\/a>, Proxy Fight<\/a><\/div>\n

\t\tRyan McBride wrote:<\/strong><\/p>\n

Activist investor Carl Icahn has increased his stake in Cambridge, MA-based biotech firm Genzyme (NASDAQ:GENZ<\/a>) from 1.5 million shares in the fourth quarter of 2009 to 4.6 million shares as of last week, Bloomberg<\/em> reported last Friday. Icahn did not comment on his enlarged stake in Genzyme, according to Bloomberg<\/a><\/em>, but his previous buying sprees of biotech stocks have led to proxy fights with firms such as Cambridge, MA-based biotech Biogen Idec (NASDAQ:BIIB<\/a>), San Diego-based Amilyn Pharmaceuticals (NASDAQ:AMLN<\/a>), and drug developer Imclone Systems, which was acquired by drug giant Eli Lilly in 2008.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Life Sciences, Biotech, Proxy Fight Ryan McBride wrote: Activist investor Carl Icahn has increased his stake in Cambridge, MA-based biotech firm Genzyme (NASDAQ:GENZ) from 1.5 million shares in the fourth quarter of 2009 to 4.6 million shares as of last week, Bloomberg reported last Friday. Icahn did not comment on his enlarged stake in Genzyme, […]<\/p>\n","protected":false},"author":2829,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-326674","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/326674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2829"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=326674"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/326674\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=326674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=326674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=326674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}